Alkylgold(III) Complexes Undergo Unprecedented Photo-Induced β-Hydride Elimination and Reduction for Targeted Cancer Therapy

Angew Chem Int Ed Engl. 2022 Apr 11;61(16):e202201103. doi: 10.1002/anie.202201103. Epub 2022 Feb 21.

Abstract

Spatiotemporally controllable activation of prodrugs within tumors is highly desirable for cancer therapy to minimize toxic side effects. Herein we report that stable alkylgold(III) complexes can undergo unprecedented photo-induced β-hydride elimination, releasing alkyl ligands and forming gold(III)-hydride intermediates that could be quickly converted into bioactive [AuIII -S] adducts; meanwhile, the remaining alkylgold(III) complexes can photo-catalytically reduce [AuIII -S] into more bioactive AuI species. Such photo-reactivities make it possible to functionalize gold complexes on the auxiliary alkyl ligands without attenuating the metal-biomacromolecule interactions. As a result, the gold(III) complexes containing glucose-functionalized alkyl ligands displayed efficient and tumor-selective uptake; notably, after one- or two-photon activation, the complexes exhibited high thioredoxin reductase (TrxR) inhibition, potent cytotoxicity, and strong antiangiogenesis and antitumor activities in vivo.

Keywords: Anti-Cancer Metallodrug; Gold Medicine; Metal Prodrug; Photoactivated Chemotherapy; Thioredoxin Reductase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Coordination Complexes* / pharmacology
  • Coordination Complexes* / therapeutic use
  • Gold
  • Humans
  • Ligands
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Thioredoxin-Disulfide Reductase

Substances

  • Antineoplastic Agents
  • Coordination Complexes
  • Ligands
  • Gold
  • Thioredoxin-Disulfide Reductase